Kornimate/medical-research-clean huggingface dataset:
effect of zirconia implant supported pekk crowns versus lithium disilicate crowns on esthetics

Conditions: Tooth Loss

Summary: aim of study is to evaluate esthetic and biomechanical outcome of maxillary anterior single-tooth zirconia implant supported pekk crowns compared to lithium disilicate crowns on pekk abutments .

high performance polymers may be a valid alternative to other conventional materials for abutments and crowns over zirconia implants because of their cushioning effect and elastic modulus (5.1gpa), which absorb occlusal forces and avoid overload of the underlying bone from the direct transmission of biting impacts ; which could optimize and preserve osseointegration with time. zirconia implants with high performance polymers restorations can be considered a good alternative for replacing natural teeth. for many years lithium disilicate has been the esthetics standard used in veneers ,inlays , onlays, occlusal veneers, partial crowns,minimally invasive crowns and implant superstructures due to its natural-looking tooth colouring and excellent light-optical properties. due to the promising esthetics of high performance polymers as it can be veneered with different veneering materials it would successfully restore esthetics.

Eligibility criteria:
inclusion criteria: * age \>18 years * no active intraoral or systemic disease * no pregnancy or lactation * controlled periodontal conditions * adequate bone volume to place an implant * occlusal function with a natural tooth exclusion criteria: 1. current pregnancy. 2. psychiatric disorders. 3. smokers 4. poor motivation. 5. several occlusal parafunction. 6. persistent intraoral infections. 7. severe mucosal disease. 8. active periodontitis. 9. poor oral hygiene. 10. lack of occluding dentition at implant rehabilitation level

Keywords: zirconia implants pekk crowns high performance polymer crowns
functional exercises for chronic low back pain

Conditions: Chronic Low Back Pain

Summary: non-specific low back pain is a common condition. exercise is effective treatment for chronic low back pain. we hypothesized the functional exercise group will present pain reduction and functional improvement. the purpose of this study is investigated the effectiveness of an functional exercise program for people with nonspecific chronic low back pain. patients will be randomly divided into 2 groups: control group (minimal intervention - mini back school and analgesic) and group will receive a functional exercise protocol associated with minimal intervention.


Eligibility criteria:
inclusion criteria: * aged between 18 and 50 years * low back pain for more than 3 months * low back pain with numeric pain scale between 3 - 8 cm * understand portuguese well enough to be able to fill in the questionnaires exclusion criteria: * inflammatory/rheumatological diseases, tumor, infection or vertebral fracture; * main pain as leg pain (eg: nerve root compression or herniated disc with radicular pain / radiculopathy, lateral and central stenosis) * less than 6 months after lumbar spine, lower limb or abdomen surgery * previous spinal surgery; * previous spinal infiltration for pain relief in the last 3 months; * several scoliosis; * litigation; * pregnancy; * fibromyalgia; * people who had changed physical activity or undergone physical therapy in the previous 3 months; * presence of any contraindication to exercise; * planned travel in the next 12 weeks; * geographic inaccessibility.
the effect of vinegar on glucose and lipid metabolism in subjects with impaired glucose tolerance or type 2 diabetes

Conditions: Type 2 Diabetes

Summary: this open, randomized, cross-over, placebo-controlled study aims to investigate the effects of vinegar on glucose metabolism, endothelial function and circulating lipid levels in subjects with impaired glucose tolerance or type 2 diabetes, using the arteriovenous difference technique.

subjects with igt or type 2 diabetes will be randomised to consume 20ml vinegar (6% acetic acid) or placebo before a mixed meal. plasma samples will be taken for 300min from the radial artery and from a forearm vein for measurements of glucose, insulin, triglycerides, non-esterified fatty acids (nefa) and glycerol. muscle blood flow will be measured with strain-gauge plethysmography. glucose flux will be calculated as the arteriovenous difference of glucose multiplied by the blood flow rates.

Eligibility criteria:
inclusion criteria: 1. subjects with impaired glucose tolerance or newly diagnosed type 2 diabetes before the initiation of medication therapy 2. recreationally active 3. with stable body weight and diet during the last two months. exclusion criteria: 1. any systemic disease (besides glucose abnormalities) 2. any medication therapy 3. diabetic complications
convalescent plasma therapy on critically-ill novel coronavirus (covid-19) patients

Conditions: IMMUNOTHERAPY

Summary: out of 49 early-stage critically-ill covid-19 patients, 21 patients are the experimental group who take convalescent plasma compared to 28 patients receive only conventional therapy without taking convalescent plasma. recovery or death, length of stay in hospital, and improvement in the clinical course of the disease are monitored in relation to monitoring through severe acute respiratory syndrome coronavirus 2 (sars-cov-2) rna detection via poly chain reaction (pcr), and sars-cov-2 immunoglobulin g (igg) and immunoglobulin m (igm) serological monitoring.

objectives: the current covid-19 pandemic needs unconventional therapies to tackle the resulted high morbidity and mortality. convalescent plasma is one of the therapeutic approaches that might be of benefit. methods: forty nine early-stage critically-ill covid-19 patients residing in respiratory care units (rcu) of three hospitals in baghdad, iraq were included, 21 received convalescent plasma while 28 did not receive, namely control group. recovery or death, length of stay in hospital, and improvement in the clinical course of the disease were monitored clinically along with laboratory monitoring through sars-cov-2 rna detection via pcr, and sars-cov-2 igg and igm serological monitoring.

Eligibility criteria:
inclusion criteria: * 49 critically-ill covid-19 patients are included. * all of the patients were with pneumonia and residing in rcu * age ≥ 18 y * with dyspnea and oxygen saturation less than 90% in resting state. * at their first 3 days in rcu either receiving o2 therapy, c-pap, or on ventilators. * all of the patients were residing in infectious diseases wards before being transferred to rcu. exclusion criteria: * the exclusion criteria of the covid-19 patients were: * previous allergic history to plasma or its ingredients such as sodium citrate. * cases with serious general conditions, such as severe organ dysfunction, that are not suitable for transfusion. * very late stage of the acute respiratory distress (ards) where convalescent plasma (cp) has proved to be of low therapeutic benefit
a comparison of aerobic and resistance exercise to counteract treatment side effects in men with prostate cancer

Conditions: Exercise; Prostate Cancer

Summary: prostate cancer is the second most common cancer in men. those in the intermediate/high-risk categories typically receive androgen deprivation therapy (adt) and radiotherapy. adt greatly reduces androgen production as prostate cancer is dependent on testosterone and dihydrotestosterone for its growth.the side effects of adt therapy are extensive and include changes in body composition (muscle loss, bone loss and fat gain), strength, mood, physical function, sexual function and increased cardiovascular risk and fatigue. many of these side effects can be influenced by exercise training, both resistance training and aerobic training. however, the most appropriate exercise regime for men undergoing adt has received little research attention.

although many interventions for prostate survivors emphasise resistance exercise to maintain muscle mass and strength. arguments could equally be made for programmes emphasising aerobic exercise for fatigue, anxiety, cardiovascular risk reduction and indeed overall survival. comparisons of programmes that emphasise each exercise mode are clearly required. therefore the overall purpose of this feasibility and pilot randomised control trial is to determine the feasibility and preliminary effectiveness of an aerobic emphasised exercise program (ae) verses a resistance emphasise exercise program (re) in a rehabilitation setting, over 6 months, for prostate cancer men undergoing androgen deprivation therapy (adt).

Eligibility criteria:
inclusion criteria: * \>18 years of age with a histologically diagnosed prostate cancer * prescribed adt (androgen deprivation therapy) * self-reported not to be partaking in regular exercise (structured aerobic or resistance training ≥ 2 sessions/week) in the past 3 months. * medically cleared to exercise by their oncologist exclusion criteria: * prior exposure to adt \>12 months * prior hypogonadism * established metastatic bone disease * established osteoporosis * musculoskeletal/cardiovascular and/or neurological disease that could put them at risk from exercise as judged by the attending physician.

Keywords: prostate cancer physical fitness androgen deprivation therapy exercise cancer
a trial to investigate the safety and the pharmacokinetic, pharmacodynamic characteristics of two biochaperone® glucagon formulations compared to marketed glucagen® in subjects with t1dm

Conditions: Type 1 Diabetes Mellitus

Summary: this is a single centre, double-blind, randomised, three-period crossover phase 1 trial in subjects with type 1 diabetes mellitus (t1dm). each subject will be randomly allocated to a sequence of three treatments, i.e. two single subcutaneous doses of biochaperone® glucagon (bc glucagon) formulation 1, biochaperone® glucagon formulation 2 and glucagen® hypokit®, each at the fixed doses of 50 µg and 1 mg on 3 separate dosing visits. following trial drug administration, pharmacokinetics (pk) and pharmacodynamics (pd) assessments will be carried until 4 hours. safety will be assessed during all the trial period. the total trial maximum duration for the individual subject will be up to 10 weeks.


Eligibility criteria:
inclusion criteria: * male or female patients aged between 18 and 64 years (both inclusive) * type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months prior to the screening visit * treated with daily insulin for t1dm ≥ 12 months prior to the screening visit * stable insulin treatment at least 3 months prior to the screening visit * stable disease with hba1c \<9.0 % * c peptide \<=0.30 nmol/l * body mass index (bmi) \< 30.0 kg/m2 exclusion criteria: * type 2 diabetes mellitus * previous participation in this trial. participation is defined as being randomised * receipt of any medicinal product in clinical development within 60 days prior to this trial * clinically significant abnormal haematology, biochemistry, urinalysis, or coagulation screening tests, as judged by the investigator considering the underlying disease * known or suspected hypersensitivity to the trial products or related products * severe hypoglycaemic events within one month prior to screening, as judged by the investigator * recent administration of glucagon (within 3 months prior to screening) * clinically relevant diabetic complications as judged by the investigator * women of child bearing potential not willing to use contraceptive methods
ß-specific 4 patients: study of pediatric efficacy and safety with first-line use of canakinumab

Conditions: Systemic Juvenile Idiopathic Arthritis (SJIA)

Summary: the purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study cacz885g2301e1.

this two-part open-label study was to assess 2 different canakinumab taper regimens in patients with clinical remission (inactive disease for at least 24 continuous weeks) on canakinumab treatment without concomitant corticosteroids (cs) or methotrexate (mtx). the study was also to collect long term safety and tolerability data on sjia patients treated with canakinumab.

Eligibility criteria:
inclusion criteria: cohort 1: • patients who are receiving canakinumab treatment (4 mg/kg every 4 weeks) for systemic juvenile idiopathic arthritis (sjia) and have inactive disease at the last visit in study cacz885g2301e1 cohort 2: * confirmed diagnosis of sjia as per international league against rheumatism (ilar) definition that must have occurred at least 2 months prior to enrollment with an onset of disease \< 16 years of age. * active sjia defined as having 2 or more of the following: * documented spiking, intermittent fever (body temperature \> 38°c) for at least 1 day within 1 week before first canakinumab dose; * at least 2 joints with active arthritis * c-reactive protein (crp) \> 30 mg/l (normal range \< 10 mg/l) * rash due to sjia * serositis * lymphadenopathy * hepatosplenomegaly * negative tb screen (quantiferon or, if required by local guidelines, purified protein derivative). exclusion criteria: * with active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of human immunodeficiency virus (hiv) infection, hepatitis b and hepatitis c infection. * with underlying metabolic, renal, hepatic, infectious or gastrointestinal conditions which in the opinion of the investigator immunocompromises the patient and /or places the patient at unacceptable risk for participation. * with neutropenia (absolute neutrophil count \< 1500/mm3) at screening.

Keywords: juvenile rheumatoid arthritis (jra) chronic systemic inflammatory disorder painful joints inflammation of the synovial membrane auto-immune rheumatoid disease reactive rheumatoid arthritis systemic juvenile rheumatoid arthritis (sjra)
long-term follow-up in women with early breast cancer three years of more post primary treatment

Conditions: Breast Cancer

Summary: this study evaluates whether there are pre-treatment factors such as patient characteristics, specific breast cancer type, specific treatments, toxicities, or adverse events during treatment that may impact the quality of life and function, 3 years or more after the treatment, in cancer-free subjects. there will be 2 groups. cohort a: women who participated in previous studies namely nct02167932, nct02328313, and nct03761706, will be re-contacted and consent for this study activities. cohort b: women with breast cancer, who did not receive chemotherapy, will be consented to be included in the study, and their electronic medical data will be used. furthermore, the long-term effects of treatment and a biomarker of aging cyclin-dependent kinase inhibitor 2a (cdkn2a,p16ink4a) and relation will be assessed.


Eligibility criteria:
inclusion criteria: in order to participate in this study a subject must meet all of the eligibility criteria outlined below. 1. informed consent was obtained per institutional review board guidelines to participate in the study and hipaa authorization for the release of personal health information. 2. subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designee. 3. age ≥21 years at the time of consent. 4. able to read and comprehend english. 5. no breast cancer recurrence or metastasis; no other cancer diagnosis other than basal cell or squamous cell cancers. exclusion criteria: 1. unable to read or comprehend english. 2. breast cancer recurrence or metastasis; any other cancer diagnosis other than basal cell or squamous cell cancer.

Keywords: quality of life adverse events cancer free
applying pet/mr in rectal cancer.

Conditions: Rectal Cancer

Summary: the use of the novel recently introduced pet/mr scanner is believed to be promising in rc management, providing great anatomical details and detailed metabolic characterization. preliminary data indicate it may become a strong imaging modality for staging of rc and has the potential to be used as a predictive tool guiding individualized therapy in patients receiving nt, but confirmation on prospective studies is mandatory. the use of radiomics as analysis approach may assist in achieving a better understanding of the obtained image data, and thus a more accurate disease assessment. objectives 1. to preliminary assess the potential diagnostic value of single pet/mr scan in rc staging and compare it to that of mri alone, pet/ct alone, and combined mri and pet/ct. 2. to preliminary assess the potential value of pet/mr in predicting pmr to nt. 3. to use radiomics analysis of pet/mr data to develop a quantification clinical tools that allow a more accurate and comprehensive assessment of rc patients.


Eligibility criteria:
inclusion criteria: 1.patients with newly diagnosed rc; histopathological confirmation of adenocarcinoma of colorectal origin. exclusion criteria: 1. patients younger than 18 years; 2. pregnancy; 3. other known active malignancy; 4. previous chemotherapy or radiotherapy; 5. previous pelvic operation; 6. patient that no intent / not suited for neoadjuvant therapy (including metastatic disease at presentation); contraindication to intravenous contrast agents.
a novel nomogram to predict severity of covid-19

Conditions: COVID-19 Disease; Nomogram Model

Summary: investigators use clinical data from a large sample of covid-19 disease patients to screen out biomarkers associated with disease severity. then, a novel nomogram model will be established to predict covid-19 disease severity, which could provide important assistance and supplement for clinical work. in the case of extremely shortage of front-line medical resources, patients with potential severe diseases will be timely treated with the help of the novel nomogram model.


Eligibility criteria:
inclusion criteria: * covid-19 disease patients confirmed by virus nucleic acid rt-pcr and ct exclusion criteria: * unconfirmed suspected cases * patients during pregnancy and lactation * incomplete clinical data * investigators considered patients ineligible for the trial * child patients
assessment of vitamin d role in the pathogenesis of asthma in vitamin d resistent patients

Conditions: Asthma; Vitamin D Resistant Rickets

Summary: research title: evaluation of airway reactivity, allergy and inflammatory mediators in exhaled breath condensate in vitamin d resistant rickets. aim: to assess the effect of absence of vitamin d receptors on airway reactivity, allergy and inflammatory mediators in exhaled breath condensate in a prospective study evaluating patients with vitamin d resistant rickets and in healthy controls. sample size: 40 participants in the two groups. primary end point: airway reactivity as assessed by methacholine challenge test. secondary outcome parameters: all other parameters are the secondary end points.

research title: evaluation of airway reactivity, allergy and inflammatory mediators in exhaled breath condensate in vitamin d resistant rickets. introduction: vitamin d seems to play a role in allergic and asthmatic reactions. vitamin d resistant rickets patients lack vitamin d receptors and cannot absorb vitamin d. aim: to assess the effect of absence of vitamin d receptors on airway reactivity, allergy and inflammatory mediators in exhaled breath condensate. design: prospective study evaluating these parameters in patients with vitamin d resistant rickets and in healthy controls. participant selection: the study group will consist of vitamin d resistant rickets patients followed and treated at the pediatric endocrinology department at our hospital. the study group will be compared to an age- and sex-matched healthy control group that had a negative methacholine challenge test. sample size: 40 participants in the two groups. intervention: each subject will undergo evaluation including a respiratory questionnaire, pulmonary function tests, methacholine challenge test with determination of pc20, exhaled nitric oxide (eno), and exhaled breath condensate (ebc). venous blood will be analyzed for complete blood count + eosinophils, ige levels, and vitamin d levels. prick skin test for inhaled allergens will be performed. all measurements will be evaluated in a single 3 hour visit, with no follow up study visits. primary end point: airway reactivity as assessed by methacholine challenge test. secondary outcome parameters: all other parameters are the secondary end points.

Eligibility criteria:
inclusion criteria: * vitamin d resistent rickets * age between 3 - 40 years exclusion criteria: * any chronic lung disease * febrile illness in last 2 weeks * inhaled corticosteroids over the past 2 weeks * bronchodilators over the past 24 hours * participation in any other clinical studies over the past 4 weeks

Keywords: rickets vitamin d airway hyperreactivity exhaled breath condensate
clary sage essential oil & pregnancy

Conditions: Quality of Life; Pregnancy Related

Summary: the purpose of this study is to evaluate the potential for clary sage essential oil to support overall health, wellbeing, and quality of life during the third trimester of pregnancy among otherwise healthy adult women.

women will be informed of the opportunity to participate through their care providers, childbirth educators, or doulas. if they meet inclusion criteria, they will be given a brochure describing the risks and benefits of the study and the informed consent paperwork. if they provide consent, they will be randomized to one of two groups: active essential oil and inert placebo. both groups will receive a 4-ounce bottle of oil to apply daily during the third trimester of pregnancy. those in the placebo group will be given an inert plant oil. those in the intervention group will be given the same oil with the addition of clary sage essential oil.

Eligibility criteria:
inclusion criteria: * age 20-39 * lives in the united states * pregnant, singleton * low risk * less than 27 weeks gestation exclusion criteria: * pcos diagnosis * uncontrolled hypertension (i.e. systolic/diastolic blood pressure \> 140/90) * gestational diabetes * history of preeclampsia * preterm labor * incompetent cervix * allergy to salvia sclarea or related plants * known birth defects * thyroid disease diagnosis

Keywords: clary sage essential oil aromatherapy
efficacy and safety of bicifadine in the treatment of chronic low back pain

Conditions: Chronic Low Back Pain

Summary: * the primary objectives of this placebo-controlled clinical trial are to evaluate the analgesic efficacy and safety of bicifadine 200 mg bid compared with placebo in patients with moderate to severe chronic low back pain. * the secondary objectives are to evaluate the effect of bicifadine on function and general quality of life, to evaluate safety following discontinuation of bicifadine treatment and to investigate the population pharmacokinetics of bicifadine.


Eligibility criteria:
main inclusion criteria: * patients with low back pain assessed as class 1, class 2 or class 3 according to the quebec task force classification for spinal disorders and without detectable leg weakness on neurological examination. * patients with pain categorized as class 1 according to the quebec task force classification must have a roland-morris disability rating of \>17 at baseline to qualify. patients with pain categorized as class 2 or class 3 according to the quebec task force classification must have a roland-morris disability rating of at least 10 at baseline to qualify. * patients must have required daily analgesics for the treatment of low back pain for at least 3 months prior dosing. main exclusion criteria: * patients may not have persistent moderate or severe pain in a location other than the lower back (with the exception of radiation to the lower extremity). * patients must not have had lower back surgery within 6 months prior to baseline, nor epidural corticosteroid injections within 3 months prior to baseline. * patients may not have an unstable medical condition.

Keywords: bicifadine chronic low back pain